pISSN 2636-0004eISSN 2636-0012
pISSN 2636-0004Patient Characteristics
| Variable | Value |
|---|---|
| No. of patients | 72 |
| Sex | |
| Male | 47 |
| Female | 25 |
| Mean age (yr) | 73.6 ± 8.3 (53–85) |
| Child-Pugh Class | |
| A | 51 |
| B | 20 |
| C | 1 |
| Etiology | |
| Hepatitis C | 43 |
| Hepatitis B | 13 |
| Hepatitis B + C | 3 |
| Alcohol | 3 |
| Unknown | 10 |
| ECOG performance status | |
| 0 | 71 |
| 1 | 1 |
| Number of tumors in the caudate lobe | |
| Single | 68 |
| 2 | 3 |
| 3 | 0 |
| 4 | 1 |
| Mean tumor size (mm) | 18.6 ± 9.9 (6–53) |
| Subsegment of the caudate lobe | |
| Spiegel lobe | 30 |
| Paracaval portion | 38 |
| Caudate process | 11 |
| Number of tumors in other sites | |
| None | 24 |
| 1–5 | 33 |
| 5–10 | 7 |
| ≥ 11 | 8 |
| Prior treatment | |
| None | 27 |
| Conventional TACE alone | 37 |
| Hepatectomy plus TACE | 6 |
| Hepatectomy plus HAIC plus TACE | 1 |
| RFA plus TACE | 1 |
| Mean AFP level (ng/mL) | 527.0 ± 1,866.1 (2–8,240) |
| Mean PIVKA-II level (mAU/mL) | 412.3 ± 1,217.0 (10–7,685) |
Values are presented as number only or mean ± standard deviation (range)
ECOG, European Cooperative Oncology Group; HAIC, hepatic arterial infusion chemotherapy; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; AFP, alpha fetoprotein; PIVKA-II, protein induced by absence of vitamin K or antagonist-II